Sanofi Records Q4 Topline, Bottomline Growth As Blockbuster Eczema Drug Soars


Sanofi SA's SNY Q4 FY21 sales grew 4.1% to €9.99 billion, +6.5% (+4.1% on constant exchange rates).

  • Business EPS came in at €1.38, compared with €1.22 a year ago.
  • For FY21, Business EPS rose by 15.5% at CER, while the company had guided for a rise of 14%.
  • The gross profit margin expanded 240 basis points to 69.5%, and the business operating profit margin increased from 21.9% to 22.6%.
  • The decline in flu vaccines weighed on sales in Q4. Net sales from Vaccines fell 6.5% at CER despite strong Europe sales, reflecting low U.S. influenza vaccination rates, which resulted from the prioritization of COVID-19 booster vaccinations.
  • Influenza vaccines sales decreased 12.4%, reaching €1.09 billion.
  • Q4 FY21 Pharmaceutical sales increased 7.4% to €6.9 billion, mainly driven by the Specialty Care portfolio (up 21.3%) with the continued strong performance of Dupixent while sales in General Medicines decreased 3.8%. Dupixent sales increased 53.1% to €1.55 billion.
  • Sanofi expects to report the late-stage trial results for its COVID-19 vaccine, developed with GlaxoSmithKline Plc GSK, in Q1 FY22. 
  • The companies said in December that the shot has promise as a booster.
  • Guidance: Sanofi, hoping for a comeback after losing ground in the COVID-19 jab race, said it aimed to increase its business EPS in the "low double-digit" at CER in 2022.
  • Price Action: SNY shares closed lower by 0.15% at $52.46 on Thursday.
Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: BiotechEarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!